https://scholars.lib.ntu.edu.tw/handle/123456789/496069
標題: | Sitagliptin and heart failure hospitalization in patients with type 2 diabetes | 作者: | CHIN-HSIAO TSENG | 關鍵字: | Heart failure; Hospitalization; Incretin; Sitagliptin; Taiwan | 公開日期: | 2016 | 出版社: | Impact Journals LLC | 卷: | 7 | 期: | 38 | 起(迄)頁: | 62687-62696 | 來源出版物: | Oncotarget | 摘要: | This study evaluated the risk of heart failure hospitalization in a 1:1 matched pair sample of sitagliptin ever and never users derived from the Taiwan's National Health Insurance. A total of 85,859 ever users and 85,859 never users matched on 8 digits of propensity score were followed for the first event of heart failure hospitalization until December 31, 2011. The treatment effect (for ever versus never users, and for tertiles of cumulative duration of therapy) was estimated by Cox regression incorporated with the inverse probability of treatment weighting using propensity score. Additionally, adjusted hazard ratios for heart failure were estimated for the baseline characteristics in sitagliptin ever users. Results showed that the incidence of heart failure hospitalization was 1,020.16 and 832.54 per 100,000 personyears, respectively, for ever and never users, with an overall hazard ratio (95% confidence intervals) of 1.262 (1.167-1.364). While compared to never users, the respective hazard ratio for the first, second, and third tertile of cumulative duration < 3.7, 3.7-10.3 and > 10.3 months was 2.721 (2.449-3.023), 1.472 (1.318-1.645) and 0.515 (0.447-0.594). Older age, longer diabetes duration, male sex, and use of insulin, sulfonylurea, calcium channel blockers, aspirin, ticlopidine, clopidogrel and dipyridamole were significantly associated with a higher risk in sitagliptin users, but dyslipidemia and use of metformin and statin were protective. In conclusion, sitagliptin increases the risk of heart failure hospitalization within one year of its use, but reduces the risk thereafter. Some factors predisposing to sitagliptin-related heart failure are worthy of attention in clinical practice. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991765467&doi=10.18632%2foncotarget.10507&partnerID=40&md5=1fa14fb9571ead786df20597f080210a https://scholars.lib.ntu.edu.tw/handle/123456789/496069 |
ISSN: | 1949-2553 | DOI: | 10.18632/oncotarget.10507 | SDG/關鍵字: | acetylsalicylic acid; calcium channel blocking agent; clopidogrel; dipyridamole; insulin; metformin; sitagliptin; sulfonylurea; ticlopidine; antidiabetic agent; sitagliptin; adult; age; Article; cardiovascular risk; cohort analysis; comparative study; controlled study; disease association; disease duration; drug effect; drug exposure; drug use; dyslipidemia; female; heart failure; hospitalization; human; incidence; major clinical study; male; middle aged; non insulin dependent diabetes mellitus; risk factor; sex difference; Taiwan; treatment duration; aged; complication; diabetic complication; health insurance; heart failure; hospitalization; non insulin dependent diabetes mellitus; probability; proportional hazards model; regression analysis; Adult; Aged; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Incidence; Insurance, Health; Male; Middle Aged; Probability; Proportional Hazards Models; Regression Analysis; Sitagliptin Phosphate; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。